Clinical trial
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Recruiting now · Not applicable · 1 countries · Registry ID NCT06689241
Recruiting nowNot applicableInterventional
What this study is about
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age20 Years to 60 Years
SexAll
Healthy volunteersAccepted
ConditionMorbid Obesity, Bariatric Surgery Candidate
Full registry criteria
Inclusion Criteria: * Age: 20-60 years, both sexes. * ASA physical status class I to III. * BMI 35-50 kg/m² Exclusion Criteria: * Severe cardiac disorder * chronic renal failure * liver cirrhosis * major psychological disorder
Treatments and study arms
Enoxaparin
Drug
40mg
rivaroxaban
Drug
10mg
Primary outcomes
Incidence of thromboembolic eventsmonth 3 postoperative
deep vein thrombosis, pulmonary thromboembolism, mesenteric vascular occlusion
Study locations
1 locations were listed when this page was built. The first 40 are shown.